| Zejula (niraparib) / GSK, J&J |
| Completed | N/A | 2336 | Europe | olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib | University Hospital, Caen | Cancer | 05/21 | 09/22 | | |
MITO 34, NCT04617470: Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study |
|
|
| Recruiting | N/A | 300 | Europe | | Fondazione Policlinico Universitario Agostino Gemelli IRCCS, GlaxoSmithKline | Ovarian Cancer | 01/22 | 01/22 | | |
ROMP, NCT04582552: The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer |
|
|
| Recruiting | N/A | 60 | RoW | PARP inhibitors, Lynparza, Zejula | Xiaoxiang Chen | Ovarian Cancer, Clinical Marker, PARP Inhibitor | 05/22 | 11/23 | | |
REFIRM, NCT06086665: The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer |
|
|
| Completed | N/A | 850 | RoW | Niraparib | Asan Medical Center, Samsung Medical Center, Seoul National University Hospital, Severance Hospital, Gangnam Severance Hospital, Keimyung University Dongsan Medical Center, Kyungpook National University Chilgok Hospital, Seoul St. Mary's Hospital, National Cancer Center, Korea, Pusan National University Yangsan Hospital, Inje University, Pusan National University Hospital | Epithelial Ovarian Cancer | 10/22 | 10/22 | | |
NCT05734911: Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study |
|
|
| Completed | N/A | 199 | RoW | Niraparib | Zhongda Hospital | Ovarian Neoplasms | 12/22 | 02/23 | | |
NCT05401214: Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination) |
|
|
| Approved for marketing | N/A | | Europe, RoW | Niraparib plus Abiraterone Acetate (Nira/AA) combination, Prednisone/Prednisolone | Janssen Research & Development, LLC | Metastatic Castration-resistant Prostate Cancer | | | | |
NCT05749211: Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer |
|
|
| Not yet recruiting | N/A | 59 | NA | Huaier granule, Niraparib | Ruijin Hospital | Ovarian Cancer | 12/23 | 12/25 | | |
NCT06037213: A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib |
|
|
| Recruiting | N/A | 500 | RoW | | Peking Union Medical College Hospital | Ovarian Cancer | 12/23 | 01/24 | | |
| Recruiting | N/A | 350 | Europe | Niraparib | Royal Marsden NHS Foundation Trust | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 02/24 | 02/24 | | |
ChiCTR2200064890: Efficacy and Safety of Avatrombopag in Patients with Thrombocytopenia of Ovarian Cancer Treated with Niraparib |
|
|
| Not yet recruiting | N/A | 67 | | Avatrombopag | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Self selected topic: Efficacy and Safety of Avatrombopag in Patients with Thrombocytopenia of Ovarian Cancer Treated with Niraparib(SKX-CIT-2210) | Thrombocytopenia in patients with ovarian cancer | | | | |
NCT04589039: A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea |
|
|
| Recruiting | N/A | 600 | RoW | | Takeda | Ovarian Neoplasms | 12/24 | 12/24 | | |
CONOR, NCT05857397: A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America |
|
|
| Recruiting | N/A | 96 | RoW | Observational study | Latin American Cooperative Oncology Group, GlaxoSmithKline | Ovarian Cancer | 04/25 | 04/25 | | |
NCT05021562: A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice |
|
|
| Recruiting | N/A | 300 | Japan | Niraparib | Takeda | Ovarian Cancer | 03/26 | 03/26 | | |
ChiCTR2300068357: A multicenter clinical trial study of the PARP inhibitor niraparib combined with radiation therapy in the treatment of children with H3K27M mutation diffuse intrinsic pontine glioma (DIPG) |
|
|
| Recruiting | N/A | 40 | | None Treatment ;Radiation therapy (60 Gy) ;Radiation therapy (60 Gy) + Niraparib (100 mg/d) | The Third Affiliated Hospital of Zhengzhou University; The Third Affiliated Hospital of Zhengzhou University, The Third Affiliated Hospital of Zhengzhou University | Pediatric diffuse intrinsic pontine gliomas | | | | |
